Curis, Inc. (CRIS)
$
1.7
-0.12 (-7.06%)
Key metrics
Financial statements
Free cash flow per share
-2.4119
Market cap
21.2 Million
Price to sales ratio
1.8631
Debt to equity
-2.3213
Current ratio
0.7443
Income quality
0.7826
Average inventory
0
ROE
4.4068
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Curis, Inc., a biotechnology company focused on discovering and developing drug candidates for human cancers in the United States, reported selling, general, and administrative expenses of $16,790,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is 6,306,284.00 reflecting potential dilution effects that could impact shareholder value. The net total of other income and expenses is $1,153,000.00 which showcases the company's non-core financial activities. The EBITDA is -$42,571,000.00 serving as a key indicator of the company's operational profitability, while the net income ratio is -3.98 reflecting the company's profitability margin. The clinical-stage pipeline features candidates such as Emavusertib, which is currently in a Phase 1/2 clinical trial targeting non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Additionally, CI-8993, a monoclonal antibody, is designed to antagonize the V-domain Ig suppressor of T cell activation. Other notable candidates include Fimepinostat, CA-170, and CA-327, each targeting various oncology indications. Curis has established collaboration agreements with significant industry players, including F. Hoffmann-La Roche Ltd. and Genentech Inc. for the commercialization of Erivedge, and with Aurigene Discovery Technologies Limited to advance small molecule compounds in immuno-oncology and precision oncology. The stock is affordable at $1.72 making it suitable for budget-conscious investors. Additionally, the stock has a low average trading volume of 106,340.00 indicating lower market activity and possibly affecting liquidity. With a market capitalization of $21,248,130.00 the company is classified as a small-cap player within the financial landscape. Curis, Inc. is a key player in the biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, where it drives innovation and growth. This combination of affordability, market positioning, and sector engagement highlights Curis, Inc.'s potential as it navigates the evolving landscape of cancer treatment and biotechnology development.
Is Curis, Inc. (CRIS) a good investment?
Investing in Curis, Inc. (CRIS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Curis, Inc. (CRIS)'s stock forecast?
Analysts predict Curis, Inc. stock to fluctuate between $1.02 (low) and $6.44 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Curis, Inc.'s market capitalization?
As of 2025-09-16, Curis, Inc.'s market cap is $21,248,130, based on 12,498,900 outstanding shares.
How does Curis, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Curis, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Curis, Inc. (CRIS) stock?
To buy Curis, Inc. (CRIS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRIS. Place an order (Market, Limit, etc.).
What is the best time to invest in Curis, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Curis, Inc. stock ever split?
Curis, Inc.'s last stock split was 1:20 on 2023-09-29.
How did Curis, Inc. perform in the last earnings report?
Revenue: $10,908,000 | EPS: -$6.88 | Growth: -23.21%.
Where can I find Curis, Inc.'s investor relations reports?
Visit https://www.curis.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Curis, Inc.?
You can explore historical data from here
What is the all-time high and low for Curis, Inc. stock?
All-time high: $180.80 (2021-08-31) | All-time low: $1.02 (2025-04-09).
What are the key trends affecting Curis, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Curis, Inc. (NASDAQ:CRIS ) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Presentation Li Wang Watsek Research Analyst Hey, everyone. Welcome to our next session with Curis.
seekingalpha.com
Curis, Inc. (NASDAQ:CRIS ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Presentation James Dentzer President, CEO, Secretary, Treasurer & Director Good afternoon.
prnewswire.com
LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Global Healthcare Conference 2025 being held September 3 – 5, 2025.
fool.com
Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.
seekingalpha.com
Curis, Inc. (NASDAQ:CRIS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Ahmed M. Hamdy - Chief Medical Officer Diantha Duvall - CFO and Principal Financial & Accounting Officer James E.
prnewswire.com
LEXINGTON, Mass. , July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m.
prnewswire.com
LEXINGTON, Mass. , July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 1,538,460 shares ("Shares") of its common stock in a registered direct offering priced at-the-market under Nasdaq rules.
seekingalpha.com
Curis, Inc. (NASDAQ:CRIS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Ahmed Hamdy - Chief Medical Officer Jonathan Zung - Chief Development Officer Conference Call Participants Li Watsek - Cantor Fitzgerald Kripa Devarakonda - Truist Securities Operator Good morning ladies and gentlemen and welcome to the Curis Provides First Quarter 2025 Business Update Conference Call. At this time, all lines are in listen-only mode.
prnewswire.com
LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m.
prnewswire.com
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.
See all news
